5 Things to Know About Advances in Oral Treatment for Hepatitis C

In a recent study published in The New England Journal of Medicine researchers led by Mark Sulkowski, MD, of Johns Hopkins University in Baltimore examined the outcomes of an oral combination therapy of declatasvir and sofosbuvir in patients infected with hepatitis C genotype 1, 2 or 3.

Over the course of the study 211 patients received treatment.

•    Patients infected with genotype 1: 98 percent of previously untreated patients had a sustained virologic response at week 12 after the end of therapy.
•    Patients infected with genotype 1: 98 percent of previously treated patients who did not have a sustained virologic response with HCV protease inhibitors had a sustained virologic response at week 12 after the end of therapy.
•    Patients infected with genotype 2: 92 percent had a sustained virologic response at week 12.
•    Patients infected with genotype 3: 89 percent had a sustained virologic response at week 12.
•    The most common adverse events included nausea, headache and fatigue.

More Articles on Gastroenterology:
EndoChoice Launches Study to Demonstrate Clinical Significance of Fuse Endoscopy System
5 Current Treatments for Ulcerative Colitis
Dr. Michael Uzer Joins Sarah Bush Lincoln Health Center

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast